Central Nervous System Carcinoma clinical trials at University of California Health
1 research study open to eligible people
See if Memantine Protects the Brain During Radiation Therapy Treatment for Primary Central Nervous System Tumors
open to eligible people ages 4-17
This phase III trial compares memantine to usual treatment in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.
Our lead scientists for Central Nervous System Carcinoma research studies include Alyssa T. Reddy.